指南与共识妇科

酪氨酸激酶抑制剂毒性:妇科肿瘤学会综述与推荐

Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations.
指南 / 共识 · Gynecol Oncol · 2023-05-17

妇科肿瘤学会以委员会方式综述酪氨酸激酶抑制剂(TKI)在妇科恶性肿瘤中的用法与毒性管理,指出TKI可提高部分既往无有效二线标准治疗患者的缓解率与持久缓解,但药物相关毒性显著,常需减量或延迟给药;需关注费用与财务毒性,未来需扩展分子驱动人群研究。

要点

  • TKI可潜在提高部分既往无有效二线标准治疗患者的缓解率和持久缓解。
  • 仑伐替尼联合帕博利珠单抗针对子宫内膜癌驱动因素更精准,但药物相关毒性显著,常需减量和延迟给药。
  • 毒性管理需频繁随访并寻找最高可耐受剂量;TKI费用高,财务毒性与药物副作用同等重要,应充分利用患者援助项目。

核心结论

  • 未来研究需将TKI扩展至新的分子驱动人群。
  • 需关注费用、缓解持久性和长期毒性管理,以确保所有符合条件的患者获得治疗。

研究设计与样本

  • 妇科肿瘤学会以委员会方式对TKI在妇科癌症中应用的医学文献进行全面综述。
  • 汇编每种药物的详细信息、分子靶点及临床疗效和副作用的相关数据,并收集药物继发效应及特定毒性管理策略(包括减量和合并用药)信息。

主要发现

  • TKI可潜在为既往无有效标准二线治疗的一组患者提供改善的缓解率和持久缓解。
  • 仑伐替尼联合帕博利珠单抗代表针对子宫内膜癌驱动因素的更精准方法;但仍存在显著药物相关毒性,因此经常需要减量和延迟给药。
  • 毒性管理需要频繁随访和管理策略,以帮助患者找到最高可耐受剂量。
  • TKI价格昂贵,患者财务毒性与任何药物副作用一样是衡量药物效用的关键指标。
  • 许多此类药物有患者援助项目,应充分利用以尽量减少费用。

关键数值与推荐

  • 原文未报告具体推荐等级、剂量、阈值或统计数值。

临床怎么用

  • 毒性管理需频繁随访和管理策略,以帮助患者找到最高可耐受剂量。
  • 应充分利用患者援助项目以尽量减少费用。
  • 未来研究需将TKI扩展至新的分子驱动人群,并关注费用、缓解持久性和长期毒性管理。

局限性

  • 未来研究需要将TKI扩展至新的分子驱动人群。
  • 需要关注费用、缓解持久性和长期毒性管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Oral tyrosine kinase inhibitors (TKIs) have new indications for treatment in gynecologic malignancies. These targeted drugs have both unique and overlapping toxicities, which require careful attention and management. New combination therapies with immune-oncology agents have demonstrated promise in endometrial cancer. This review examines common adverse events associated with TKIs and provides readers with an evidence-based review on current uses and strategies for the management of these medications. METHODS: A comprehensive review of the medical literature on TKI use in gynecologic cancer was undertaken by a committee approach. Details of each drug, its molecular target, and relevant data on both clinical efficacy and side effects were compiled and organized for clinical use. Information on drug-related secondary effects and management strategies for specific toxicities, including dose reduction and concomitant medications, were gathered. RESULTS: TKIs can potentially offer improved response rates and durable responses for a group of patients who were previously without an effective standard second-line therapy. The combination of lenvatinib and pembrolizumab represents a more targeted approach to the drivers of endometrial cancer; however, there remains significant drug-related toxicity, and thus dose reduction and dose delay are frequently required. Toxicity management requires frequent check-ins and management strategies to help patients find the highest tolerable dose. TKIs are expensive and patient financial toxicity is as critical a measure of a drug's utility as any drug side effect. Many of these drugs have patient assistance programs, which should be fully utilized to minimize cost. CONCLUSIONS: Future studies are needed to expand the role of TKIs into new molecularly driven groups. Attention to cost, durability of response, and long-term toxicity management is needed to ensure all eligible patients have access to treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rimel BJ, Crane EK, Hou J, et al. Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations. Gynecol Oncol. 2023. PMID: 37207499. doi:10.1016/j.ygyno.2023.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。